What it's for (Indications)
- Dinoprostone, a synthetic prostaglandin E2 (PGE2), is primarily indicated for various obstetric applications focused on cervical ripening and uterine contraction.
- Its main uses include the induction of labor at or near term in pregnant women with an unfavorable cervix who require labor initiation for medical reasons.
- This includes situations where continuing the pregnancy poses a risk to the mother or fetus, or when gestation has progressed beyond the expected due date without spontaneous labor.
- Furthermore, it is utilized for the therapeutic interruption of pregnancy during the second trimester, aiding in the expulsion of uterine contents in cases such as fetal anomaly or maternal medical indication for abortion.
- Dinoprostone also plays a critical role in the management of missed abortion or intrauterine fetal death (IUFD), facilitating the evacuation of the uterus in these challenging clinical scenarios where spontaneous expulsion is delayed or incomplete.
- These applications leverage its specific effects on cervical tissue and myometrial contractility to achieve desired obstetric outcomes, promoting a more efficient and safer delivery process or uterine evacuation.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage and administration of dinoprostone vary significantly based on the specific indication, patient's clinical status, and the formulation used. For cervical ripening and labor induction, a common approach involves the use of a controlled-release vaginal insert (e.g., 10 mg), designed to release dinoprostone gradually over a period of 12 hours. This insert is typically removed after 12 hours of placement or upon the onset of active labor, or if uterine hyperstimulation occurs. Alternatively, a vaginal gel formulation (e.g., 0.5 mg) can be administered into the posterior fornix, with the option to repeat the dose after 6 hours if cervical ripening is deemed insufficient, not exceeding a total cumulative dose of 1.5 mg within a 24-hour period. For the induction of abortion or evacuation of uterine contents in cases of missed abortion or IUFD, a vaginal suppository (e.g., 20 mg) is generally administered every 3 to 5 hours until the abortion occurs or the uterus is evacuated, with a maximum recommended cumulative dose not exceeding 240 mg. Careful adherence to specific product dosing guidelines, continuous maternal and fetal monitoring, and individualized patient assessment are crucial to optimize efficacy and minimize potential risks. |
Safety & Warnings
Common Side Effects
- Dinoprostone, while effective for its intended obstetric purposes, is associated with a range of potential side effects, primarily attributable to its potent uterotonic and systemic prostaglandin effects.
- Maternal side effects frequently include uterine hyperstimulation, characterized by tachysystole (excessive frequency of contractions, often defined as more than 5 contractions in 10 minutes over 30 minutes) or hypertonus (abnormally strong and prolonged contractions), which can lead to significant complications such such as fetal distress or uterine rupture.
- Gastrointestinal disturbances are also common, presenting as nausea, vomiting, and diarrhea due to systemic prostaglandin effects.
- Other reported maternal adverse events include fever (prostaglandin-induced pyrexia), back pain, headache, dizziness, and hypotension.
- On the fetal side, the most critical adverse effects are directly related to uterine hyperstimulation, manifesting as fetal distress, abnormal fetal heart rate patterns (e.
- g.
- , prolonged decelerations, bradycardia, or tachycardia), and meconium passage, which may indicate fetal hypoxia.
- Although less common, severe allergic reactions, including bronchospasm and anaphylaxis, have been reported.
- The potential for uterine rupture and disseminated intravascular coagulation (DIC) represents severe, albeit rare, complications requiring immediate clinical attention and intervention.
Serious Warnings
- Black Box Warning: While dinoprostone does not officially carry an FDA-mandated 'Black Box Warning' in the strict sense, its use is associated with several serious and potentially life-threatening risks that warrant a detailed and prominent safety alert. These high-risk factors necessitate administration exclusively within a hospital setting, equipped with immediate access to continuous electronic fetal monitoring, comprehensive obstetrical care, and emergency facilities for operative delivery (e.g., Cesarean section). Key serious warnings include a significant risk of **uterine hyperstimulation** (tachysystole or hypertonus), which can lead to **fetal distress**, **placental abruption**, and, most severely, **uterine rupture**, particularly in patients with a history of uterine surgery (e.g., prior C-section scar, myomectomy) or grand multiparity. Continuous electronic fetal monitoring is paramount to detect non-reassuring fetal heart rate patterns promptly, such as prolonged decelerations or bradycardia. There is also an observed increased risk of **disseminated intravascular coagulation (DIC)** postpartum, especially in older mothers (aged 30 years or more), those with complications during pregnancy (e.g., pre-eclampsia, gestational diabetes), or prolonged gestation (gestational age greater than 40 weeks). Additionally, severe **hypersensitivity reactions**, including anaphylaxis and bronchospasm, and the rare but life-threatening event of **amniotic fluid embolism** are potential concerns. Due to these critical safety considerations, judicious patient selection, meticulous dosing, and intensive maternal and fetal monitoring are indispensable when using dinoprostone to ensure the safest possible outcome for both mother and infant.
- The use of dinoprostone necessitates extreme caution and vigilant monitoring due to its potent pharmacological effects and potential for serious complications.
- It should only be administered in a hospital setting where continuous fetal monitoring and immediate access to comprehensive obstetrical care, including facilities for emergency operative delivery (e.
- g.
- , Cesarean section), are readily available.
- A significant warning concerns the risk of uterine hyperstimulation, which can result in fetal distress, placental abruption, and uterine rupture, particularly in women with previous uterine surgery (e.
- g.
- , prior C-section scar, myomectomy) or grand multiparity.
- Patients with a history of asthma, glaucoma, or increased intraocular pressure should receive dinoprostone with extreme caution, as systemic absorption of prostaglandins can exacerbate these conditions.
- There is an increased risk of disseminated intravascular coagulation (DIC) in women undergoing labor induction, especially those over 30 years of age, with complications during pregnancy (e.
- g.
- , pre-eclampsia, gestational diabetes), or with a gestational age greater than 40 weeks; clinicians should be vigilant for signs and symptoms of DIC.
- Postpartum hemorrhage and amniotic fluid embolism, though rare, also represent serious potential warnings.
- Concomitant use with other oxytocic agents (e.
- g.
- , oxytocin) must be carefully timed to avoid excessive uterine activity; typically, a waiting period of at least 6-12 hours after dinoprostone removal or last dose is recommended before initiating other uterotonics.
How it Works (Mechanism of Action)
Dinoprostone functions as a synthetic equivalent of naturally occurring prostaglandin E2 (PGE2), exerting its primary pharmacological effects on the cervix and uterine musculature. Its mechanism of action for cervical ripening involves directly influencing the biochemical and structural integrity of the cervix. Dinoprostone stimulates the activity of collagenase enzymes, which are crucial for breaking down the rigid collagen fibers that contribute to cervical firmness. Concurrently, it increases the water content of the cervical tissue and alters the extracellular matrix composition. These changes collectively lead to a softening, effacement (thinning), and dilation of the cervix, thereby rendering it more 'favorable' or 'ripe' for the progression of labor. Regarding uterine contractility, dinoprostone binds to specific prostaglandin receptors (EP1, EP2, EP3, EP4) located on the myometrial smooth muscle cells. This binding initiates intracellular signaling cascades, primarily leading to an increase in intracellular calcium concentrations within the myometrial cells. The elevated calcium levels trigger powerful, synchronized, and rhythmic uterine contractions, mimicking natural labor. These coordinated contractions are essential for the progression of labor, the expulsion of uterine contents during abortion, or for the evacuation of the uterus in cases of fetal demise. The dual action of cervical ripening and uterine stimulation makes dinoprostone a potent and effective agent for various obstetric indications.